Given that loss‐of‐function in NLRP10 promotes skin inflammation in humans and that mice lacking NLRP10 develop intestinal inflammation,97, 98 strategies aimed at activating NLRP10 could lead to new anti‐inflammatory therapies. Here, NLRP10 is linked to gastroenteritis.